La Jolla Pharmaceutical is a biotechnology business based in the US. La Jolla Pharmaceutical shares (LJPC) are listed on the NASDAQ and all prices are listed in US Dollars. La Jolla Pharmaceutical employs 61 staff and has a trailing 12-month revenue of around $46.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $5.11 |
| 200-day moving average | $4.46 |
| Wall St. target price | $6.23 |
| PE ratio | 47.8462 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.13 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing La Jolla Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of La Jolla Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
La Jolla Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, La Jolla Pharmaceutical shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Revenue TTM | $46.5 million |
|---|---|
| Gross profit TTM | $63.1 million |
| Return on assets TTM | -1.52% |
| Return on equity TTM | 0% |
| Profit margin | 8.54% |
| Book value | $-0.61 |
| Market Capitalization | $155.1 million |
TTM: trailing 12 months
We're not expecting La Jolla Pharmaceutical to pay a dividend over the next 12 months.
La Jolla Pharmaceutical's shares were split on a 1:50 basis on 13 January 2014 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your La Jolla Pharmaceutical shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for La Jolla Pharmaceutical shares which in turn could have impacted La Jolla Pharmaceutical's share price.
Over the last 12 months, La Jolla Pharmaceutical's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while La Jolla Pharmaceutical's is 2.4079. This would suggest that La Jolla Pharmaceutical's shares are significantly more volatile than the average for this exchange and represent a higher risk.
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.